TNFSF10 and neoplasm: An intratumor injection of the TRAIL-EXOs in INT12 human melanoma-bearing mice showed a strong inhibition of tumor growth, but systemic administration failed to accomplice the anticancer effect, probably due to the poor tumor homing capacity of the vesicles under study.